Clinical research studyMyocardial Ischemic Events in ‘Real World’ Patients with Atrial Fibrillation Treated with Dabigatran or Warfarin
Section snippets
Methods
We used the civil registration number assigned to all Danish residents to link 3 nationwide databases: 1) the Danish National Prescription Registry,10 which records purchase date, Anatomical Therapeutic Chemical (ATC) classification code, and package size for every prescription purchase in Denmark since 1994; 2) the Danish National Patient Register11 established in 1977, which includes admission/discharge date, and discharge International Classification of Diseases (ICD) diagnoses for >99% of
Study Population Characteristics
During the inclusion period, we identified the VKA-naïve cohort from 4818 and 8133 eligible first-time purchases of dabigatran and warfarin, respectively. The VKA-experienced cohort was identified from 3379 eligible purchases defining a switch from warfarin to dabigatran, alongside 277,937 non-first-time warfarin purchases (among 49,868 unique current VKA users). There were a comparable number of 110-mg-bid users among dabigatran users in both the VKA-naïve (44.1%) and VKA-experienced cohort
Discussion
In this large nationwide cohort study, which included both “switchers” and “new starters” on dabigatran or warfarin, we showed that in the cohort of previously VKA-naïve users (ie, “new starters” on dabigatran or warfarin) there was a nonsignificant trend to lower myocardial infarction rates with dabigatran among VKA-naïve users for both the 110-mg-bid and the 150-mg-bid dose of dabigatran relative to warfarin. In the cohort of VKA-experienced users (“switchers” to dabigatran or “continuers” on
References (23)
- et al.
Does warfarin for stroke thromboprophylaxis protect against MI in atrial fibrillation patients?
Am J Med
(2010) - et al.
Efficacy and safety of dabigatran etexilate and warfarin in “real-world” patients with atrial fibrillation: a prospective nationwide cohort study
J Am Coll Cardiol
(2013) - et al.
Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation
Chest
(2010) - et al.
A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey
Chest
(2010) - et al.
Predictive values of acute coronary syndrome discharge diagnoses differed in the Danish National Patient Registry
J Clin Epidemiol
(2009) - et al.
A new landscape for stroke prevention in atrial fibrillation: focus on new anticoagulants, antiarrhythmic drugs, and devices
Stroke
(2011) - et al.
Dabigatran versus warfarin in patients with atrial fibrillation
N Engl J Med
(2009) - et al.
The long-term multicenter observational study of dabigatran treatment in patients with atrial fibrillation (RELY-ABLE) study
Circulation
(2013) - et al.
Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial
Circulation
(2012) - et al.
Dabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomized controlled trials
Arch Intern Med
(2012)
Evaluating medication effects outside of clinical trials: new-user designs
Am J Epidemiol
Cited by (61)
Risk of Major Gastrointestinal Bleeding With New vs Conventional Oral Anticoagulants: A Systematic Review and Meta-analysis
2020, Clinical Gastroenterology and HepatologyCombining Oral Anticoagulants With Platelet Inhibitors in Patients With Atrial Fibrillation and Coronary Disease
2018, Journal of the American College of Cardiology
Funding: This study was funded by a grant from the Obel Family Foundation.
Conflict of Interest: GYHL has served as a consultant for Bayer, Astellas, Merck, Sanofi, BMS/Pfizer, Daiichi-Sankyo, Biotronik, Portola, and Boehringer Ingelheim, and has served as a speaker for Bayer, BMS/Pfizer, Boehringer Ingelheim, Daiichi-Sankyo, and Sanofi Aventis. TBL has received investigator-initiated educational grants from Bayer Healthcare and Boehringer Ingelheim, and served as a speaker for Boehringer Ingelheim, Bayer Healthcare, and BMS/Pfizer. In addition, DAL is on the Steering Committee of a Phase IV apixaban study (AEGEAN). Both GYHL and DAL have participated in various clinical trials of stroke prevention in atrial fibrillation. TBL has served as an investigator for Janssen Scientific Affairs, LLC and Boehringer Ingelheim. TBL and LHR have been on the speaker bureaus for Bayer, BMS/Pfizer, Janssen Pharmaceuticals, Takeda, Roche Diagnostics and Boehringer Ingelheim. The other authors have no conflicts of interest to declare. MR is a full-time employee of the Danish Health and Medicines Authority. The views expressed in this article reflect her personal views and do not necessarily represent the position of the Danish Health and Medicines Authority.
Authorship: TBL: original idea, wrote the first draft and made revisions; LHR, MR, DAL: interpreted data, edited and drafted revisions to the article; AGR, FS: analyzed the data, drafted and revised the paper; GYHL: co-wrote the first draft and made revisions. All authors had access to the data and a role in writing the manuscript.